We serve Chemical Name:3-Nitro-4-(trifluoromethyl)benzaldehyde CAS:102844-90-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Nitro-4-(trifluoromethyl)benzaldehyde
CAS.NO:102844-90-6
Synonyms:3-nitro-4-trifluoromethoxybenzoic acid;3-Nitro-4-trifluoromethylbenzaldehyde;4-Trifluoromethyl-3-nitro-benzaldehyde;3-Nitro-4-trifluormethoxy-benzoesaeure
Molecular Formula:C8H4F3NO3
Molecular Weight:219.11700
HS Code:
Physical and Chemical Properties:
Melting point:41-45ºC(lit.)
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:62.89000
Exact Mass:219.01400
LogP:2.94930
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-nitro-4-trifluoromethoxybenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Nitro-4-trifluormethoxy-benzoesaeure physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-nitro-4-trifluoromethoxybenzoic acid Use and application,3-nitro-4-trifluoromethoxybenzoic acid technical grade,usp/ep/jp grade.
Related News: That impacts airlines’ business, making it less financially attractive for them to fly those routes to China. 3-Nitro-4-(trifluoromethyl)benzaldehyde manufacturer Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API. 3-Nitro-4-(trifluoromethyl)benzaldehyde supplier Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API. 3-Nitro-4-(trifluoromethyl)benzaldehyde vendor FT was defined as any difficulty paying medical bills, high financial distress, cost-related medication nonadherence, food insecurity, and/or foregone/delayed care due to cost. 3-Nitro-4-(trifluoromethyl)benzaldehyde factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.
